Kim M, Lee JO, Koh J, Kim TM, et al. A phase II study of brentuximab vedotin in patients with relapsed or refractory Epstein-Barr virus-positive and CD30-positive lymphomas. Haematologica 2021;106:2277-2280.
PMID: 33792222